Fundraising FoxDioGenX
Marseille, FR · 5 known investors
Find your way into DioGenX
Each arrow is one introduction. Sign up to fill in the first one.
26 people can intro you to Jean-Pascal
Ask Luc-Emmanuel Barreau to introduce you to Jean-Pascal Tranié
You →Luc-Emmanuel · together at Aloe Private Equity →Jean-Pascal
Sign up to find every way you can get introduced to DioGenX
- Your email: who you already know at DioGenX, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the DioGenX team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes. It focuses on new treatment options for diabetic patients as an alternative to lifelong exogenous insulin.
Founders & leadership
PC
JT
Jean-Pascal TraniéCo-FounderJean-Pascal Tranié has held management roles in technology and energy sectors, including CEO positions, and brings two decades of investment experience to his co-founder role at DiogenX, a preclinical biotech company developing biologic therapeutics for Type 1 diabetes.
Investors · 5
AdBio partners✓ confirmed by DioGenXParis
How we know: AdBio partners's portfolio page · the company's own site · Not right? Tell us
Roche Venture Fund✓ confirmed by DioGenXBasel · $648K – $3.2M
How we know: Roche Venture Fund's portfolio page · the company's own site · Not right? Tell us
Boehringer Ingelheim Venture Fund✓ confirmed by DioGenXIngelheim am Rhein · $16.2M
How we know: the company's own site · Not right? Tell us
Sunstone Capital✓ confirmed by DioGenXFrederiksberg
How we know: the company's own site · the VCSheet dataset · Not right? Tell us
Related companies · 10
arGEN-XThe company develops therapies for people with severe autoimmune diseases.
GendxGenDx develops molecular diagnostic reagents, software, and services for transplant patient outcomes. Operating globally since 2005, the company serves the healthcare and diagnostics industry with specialized tools for transplant diagnostics.
Regenx BiosciencesREGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.
OrogentxOrogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.
PhigenixPhigenix develops personalized medicine for cancer, including companion diagnostics and targeted therapies for prostate and breast cancer patients. Its work centers on early detection and targeted inhibition of PAX2 and EN2 oncogenes and a cancer vaccine using Human Beta Defensin-1 (DEFB1) mRNA to direct the immune system against cancer cells.
OrigeneOriGene develops and manufactures research and diagnostic products, including large-scale GMP antibody production, with R&D and research manufacturing operations. It serves the life sciences and biotech research market from facilities in the US and Germany.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
GenedxGeneDx provides advanced genetic testing and clinical interpretation services to help clinicians diagnose rare and inherited genetic disorders, with AI-driven genomic intelligence that supports patient care decisions and accelerates research and drug discovery.
EndogenexEndogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.
GenomadixGenomadix develops the Cube, a point-of-care PCR platform for real-time molecular testing in precision medicine and environmental applications. The company commercializes FDA-cleared genotyping tests and offers its open platform for partnerships with assay developers and clinical laboratories.
Companies working in the same space as DioGenX.
Frequently asked questions
- What does DioGenX do?
- DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes. It focuses on new treatment options for diabetic patients as an alternative to lifelong exogenous insulin.
- Who founded DioGenX?
- DioGenX was founded by Benjamin Charles, Patrick Collombat, Jean-Pascal Tranié.
- Who are DioGenX's investors?
- DioGenX's investors include AdBio partners, Roche Venture Fund, Boehringer Ingelheim Venture Fund, Sunstone Capital, JDRF T1D Fund.
- Where is DioGenX headquartered?
- DioGenX is headquartered in Marseille, FR.